20.28
-0.01(-0.05%)
Currency In USD
| Previous Close | 20.29 |
| Open | 20.27 |
| Day High | 20.7 |
| Day Low | 19.94 |
| 52-Week High | 26.58 |
| 52-Week Low | 19 |
| Volume | 974,691 |
| Average Volume | 1.45M |
| Market Cap | 2.48B |
| PE | 12.29 |
| EPS | 1.65 |
| Moving Average 50 Days | 20.88 |
| Moving Average 200 Days | 22.31 |
| Change | -0.01 |
If you invested $1000 in Catalyst Pharmaceuticals, Inc. (CPRX) 10 years ago, it would be worth $5,213.37 as of September 08, 2025 at a share price of $20.28. Whereas If you bought $1000 worth of Catalyst Pharmaceuticals, Inc. (CPRX) shares 5 years ago, it would be worth $6,563.11 as of September 08, 2025 at a share price of $20.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
GlobeNewswire Inc.
Aug 26, 2025 11:12 PM GMT
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-s
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
GlobeNewswire Inc.
Aug 25, 2025 12:03 PM GMT
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-sta
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
GlobeNewswire Inc.
Aug 06, 2025 12:03 PM GMT
VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader VGCC diagno